Novo Nordisk made headlines Tuesday by announcing it would slash the list prices of its GLP-1 drugs and arguing that doing so would expand access.<\/p>\n
For insured patients who have to pay coinsurance \u2014 a certain percentage of the list price \u2014 when buying prescription drugs, or for those in high-deductible plans who need to pay list prices before meeting deductibles, the move will bring down out-of-pocket costs.<\/p>\n
But in the complicated world of drug pricing, Novo\u2019s move to cut 35% to 50% off the list price of its semaglutide products, Ozempic, Rybelus, and Wegovy, to $675 a month may not mean many more payers will cover the drugs, which would allow more people to get them. That, experts say, is because what matters to employers and other payers when making coverage decisions are net prices \u2014 the actual prices they pay after rebates and discounts.<\/p>\n
STAT+ Exclusive Story<\/p>\n
Already have an account? Log in<\/a><\/p>\n \t\t\t \t\t\t\t\t \t\t\t\tThis article is exclusive to STAT+ subscribers Already have an account? Log in<\/a><\/p>\n \t\t\t\t\t\tIndividual plans<\/p>\n \t\t\t\t\t\tGroup plans<\/p>\n![\"STAT+\"\/](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/stat-plus-breaker-bg.png\")
<\/p>\n
\n\t\t\t\t\t\t![\"STAT+\"\/](\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\"){kind=logo}
\n\t\t\t\t\t<\/a><\/p>\n
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n